Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of fibrinolytic parameters and plasminogen activator inhibitor 1 (PAI-1) promoter polymorphism on premature atherosclerosis in SLE patients.

Lupus - 1 Oct 2011

Bicakcigil M, Tasan Da, Tasdelen N, Mutlu N, Yavuz S

Abstract excerpt

Premature atherosclerosis has been recognized as a major co-morbid condition in systemic lupus erythematosus (SLE). In this study, we aimed to investigate the effect of tPA (tissue plasminogen activator) and PAI-1 (plasminogen activator inhibitor) antigen concentrations and 4G/5G polymorphism of the PAI-1 gene on the development of atherosclerosis in SLE patients. One hundred and six SLE patients, 28 Takayasu...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Atherosclerosis
Share to Carotid Intima-Media Thickness

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carotid Stenosis

Share to Coronary Vessels

Share to Fibrinolysis

Share to Plasminogen Activator Inhibitor 1

Share to Takayasu Arteritis

Share to Tissue Plasminogen Activator

Source

Identifiers

PMID: 21719525
DOI: 10.1177/0961203311404911

Genes

CAD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of fibrinolytic parameters and plasminogen activator inhibitor 1 (PAI-1) promoter polymorphism on premature atherosclerosis in SLE patients.PMID 21719525Read ↗

PECAM-1 gene polymorphisms and soluble PECAM-1 level in rheumatoid arthritis and systemic lupus erythematosus patients: any link with clinical atherosclerotic events?Semantic proximity Read ↗

Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus.Semantic proximity Read ↗

PAI and TPA gene polymorphisms in multiple sclerosis.Semantic proximity Read ↗

Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus.Semantic proximity Read ↗

Serum Levels of Anti-PON1 and Anti-HDL Antibodies as Potential Biomarkers of Premature Atherosclerosis in Systemic Lupus Erythematosus.Semantic proximity Read ↗

B-cell activating factor and related genetic variants in lupus related atherosclerosis.Semantic proximity Read ↗

Asymptomatic Carotid Atherosclerosis Cardiovascular Risk Factors and Common Hypertriglyceridemia Genetic Variants in Patients with Systemic Erythematosus LupusSemantic proximity Read ↗

A functional Ser(413)/Ser(413) PAI-2 polymorphism is associated with susceptibility and damage index score in systemic lupus erythematosus.Semantic proximity Read ↗

[PAL-1 5G/4G polymorphism in patients with systemic lupus erythematosus].Semantic proximity Read ↗

Matrix metalloproteinase-2 functional promoter polymorphism G1575A is associated with elevated circulatory MMP-2 levels and increased risk of cardiovascular disease in systemic lupus erythematosus patients.Semantic proximity Read ↗

4G/5G plasminogen activator inhibitor-1 and -308 A/G tumor necrosis factor-α promoter gene polymorphisms in Argentinean lupus patients: focus on lupus nephritis.Semantic proximity Read ↗

Factor V Leiden and prothrombin G20210A mutations and the risk of atherothrombotic events in systemic lupus erythematosus.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.